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Abstract Caveolin is a principal component of caveolae
membranes. It has been demonstrated that the interaction of
the caveolin scaffolding domain with signaling molecules can
functionally inhibit the activity of these molecules. Taxol is an
antitumor agent that suppresses microtubule dynamics and binds
to microtubules thereby stabilizing them against depolymeriza-
tion. The drug also has been implicated in the induction of
apoptosis through activation of components in signal transduc-
tion cascades. Here we have investigated the role of caveolin in
the development of drug resistance by examining the expression
of caveolins in low- and high-level drug-resistant cell lines.
Caveolin-1, but not caveolin-2, was upregulated in highly
multidrug resistant SKVLB1 cells that express high levels of
P-glycoprotein, and in low-level Taxol-resistant A549 cell lines
that express low amounts of P-glycoprotein. Two drug-resistant
A549 cell lines (one 9-fold resistant to Taxol and the other
1.5-fold resistant to epothilone B), both of which express no P-
glycoprotein, demonstrate a significant increase in the expression
of caveolin-1. These results indicate that in low-level epothilone
B- or Taxol-resistant A549 cells, increased caveolin-1 expression
occurs independently of P-glycoprotein expression. Electron
microscopic studies clearly demonstrate the upregulation of
caveolae organelles in Taxol-resistant A549 cells. Upregulation
of caveolin-1 expression in drug-sensitive A549 cells was
observed acutely beginning 48 h after incubation with 10 nM
Taxol. Thus, caveolin-1 may play a role in the development of
Taxol resistance in A549 cells.
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1. Introduction
The development of resistance to Taxol that may occur by a
variety of mechanisms is a signi¢cant problem in cancer che-
motherapy. It is known that overexpression of P-glycoprotein,
an energy-dependent drug e¥ux pump, confers multidrug re-
sistance (MDR). Taxol as well as other hydrophobic antitu-
mor drugs are substrates for P-glycoprotein, the product of
the MDR1 gene [1]. In addition to the overexpression of P-
glycoprotein, other potential mechanisms that have been im-
plicated include overexpression of c-erbB2/neu in breast can-
cer cells [2], alterations in L-tubulin isotypes [3^6], mutations
in tubulin [6], and speci¢c changes in various components of
signal transduction pathways [7,8]. Alterations in molecules
involved in signal transduction cascades, such as activation
of Raf-1 and mitogen-activated protein kinase (MAP kinase),
have been reported after treatment of drug-sensitive cells with
Taxol [7^12].
Caveolins, a family of 21^24 kDa integral membrane pro-
teins, are the principal protein components of caveolae mem-
branes. Three distinct caveolin genes, caveolin-1, caveolin-2,
and caveolin-3, have been identi¢ed [13]. Two isoforms of
caveolin-1 (Cav-1K and Cav-1L) are derived during transla-
tion utilizing alternative initiation sites. Caveolin-1 and -2 are
highly expressed in adipocytes, endothelial cells, and ¢bro-
blasts, whereas caveolin-3 is speci¢cally expressed in striated
muscle cells [13].
It has been suggested that caveolins function as sca¡olding
proteins to organize and concentrate certain caveolin-interact-
ing signaling molecules within caveolae membranes [13]. In-
teraction of the caveolin sca¡olding domain with signaling
molecules functionally suppresses the activity of these mole-
cules, suggesting that caveolin binding plays a negative regu-
latory role in signal transduction [13,14]. We have investigated
the role of caveolins in drug-resistant cells by studying the
expression of this protein in Taxol-, vinblastine-, and epothi-
lone- B-selected cells, as well as in sensitive cells treated with
Taxol.
In this report, we show that caveolin-1, but not caveolin-2,
is upregulated in a variety of drug-resistant cells. In addition,
caveolin-1 expression was increased acutely beginning 48 h
after drug-sensitive A549 cells were treated with 10 nM Taxol.
2. Materials and methods
2.1. Materials
Anti-caveolin-1 mouse IgG (mAb 2297) and anti-caveolin-2 mouse
IgG (mAb 65) were generous gifts from Dr. John R. Glenney, Trans-
duction Laboratories, and have been previously characterized [15,16].
Anti-P-glycoprotein monoclonal antibody, C219, was from Signet
Laboratories. Taxol was obtained from the Drug Development
Branch, National Cancer Institute, Bethesda, MD. Epothilone B
was kindly provided by Professor Samuel J. Danishefsky.
2.2. Cell culture
Human lung carcinoma cells, A549, together with their Taxol-re-
sistant derivatives were grown in RPMI 1640 containing 10% fetal
bovine serum (FBS). A549-T12 and A549-T24 [5] were maintained
at a ¢nal concentration of 12 and 24 nM Taxol, respectively. Two
epothilone B-resistant A549 cell lines, A549-EP0.2 and A549-EP0.3,
were derived in our laboratory as previously described for other drug-
resistant cell lines [17], and maintained in medium containing 0.2 and
0.3 nM epothilone B, respectively. Drug-sensitive (SKOV3) and vin-
blastine-resistant (SKVLB1) human ovarian carcinoma cell lines were
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gifts from Dr. V. Ling and grown in minimum essential K medium
containing 15% FBS. SKVLB1 was maintained in medium containing
1 WM vinblastine.
2.3. Preparation of plasma membranes and cell lysates
Plasma membranes from drug-sensitive and -resistant A549 and
SKOV3 cells were prepared as described [17]. To prepare cell lysates,
cells were washed twice with phosphate bu¡ered saline, lysed in bu¡er
containing 10 mM Tris-HCl, pH 7.5 and 1% SDS using 21 and 26
gauge needles, and centrifuged for 5 min at 13 000 rpm in a microfuge.
Protein concentrations of the supernatants were determined by the
method of Lowry [18].
2.4. Immunoblot analysis
Plasma membranes or cell lysates were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and trans-
ferred to nitrocellulose. Immunoblot analysis was performed as de-
scribed [11] with ECL reagents and densitometry was done to quanti-
tate the levels of caveolin-1 expression.
2.5. Reverse transcription-PCR (RT-PCR) analysis of MDR1
To determine if MDR1 was expressed in low-level epothilone B-
resistant A549 cells, RT-PCR, using speci¢c human MDR1 primers,
was performed as described [5].
2.6. Transmission electron microscopy
Samples were ¢xed with glutaraldehyde, post¢xed with osmium
tetroxide, and stained with uranyl acetate and lead citrate, as previ-
ously detailed [19,20]. Samples were examined under the Philips 410
TEM.
3. Results
3.1. Upregulation of caveolin-1 and caveolae organelles in
drug-resistant cell lines
A variety of drug-resistant cell lines were used in this study
(see Table 1). Two low-level Taxol-resistant cell lines were
derived from the human lung carcinoma cell line A549 [5].
A549-T12 that exhibited a 9-fold resistance to Taxol had a
3.4-fold increase in caveolin-1 levels as compared to parental
drug-sensitive A549 cells. No P-glycoprotein was detected in
its plasma membrane. A slightly more resistant cell line,
A549-T24 (17-fold resistant to Taxol), expressed very low lev-
els of P-glycoprotein and demonstrated a 9.5-fold increase,
compared to A549 cells, in caveolin-1 (Fig. 1A,B). An in-
creased level of caveolin-1 expression also was observed in a
highly resistant human ovarian MDR cell line SKVLB1,
which is approximately 8000- and 2500-fold resistant to Taxol
and vinblastine, respectively, as compared to its drug-sensitive
counterpart, SKOV3. In contrast, caveolin-2 levels in A549,
A549-T12 and A549-T24, and in SKOV3 and SKVLB1 cells
demonstrated no signi¢cant di¡erences (Fig. 1C).
As viewed by transmission electron microscopy, drug-sensi-
tive parental A549 cells lacked any detectable caveolae. How-
ever, A549-T24 cells show a dramatic upregulation of caveo-
lae organelles, in parallel with the upregulation of caveolin-1
expression (Fig. 2). Caveolae appear as 50^100 nm vesicles
near or attached to the plasma membrane. A similar observa-
tion was made during adipocyte di¡erentiation where upregu-
lation of caveolin-1 expression led to an increased number of
caveolae organelles in mature adipocytes, as compared with
¢broblastic pre-adipocytes [21].
3.2. Acute e¡ects of Taxol on caveolin-1 expression in A549
cells
Sixty to 70% con£uent A549 cells were treated with increas-
ing concentrations of Taxol (20^1000 nM) and the expression
of caveolin-1 in these cells was studied 20 h after drug admin-




Cell line Parental, drug-sensitive cell line Drug used for selection Fold resistance P-gpa expression Cav-1 upregulationd (fold)
SKVLB1 human ovarian SKOV3 VBLb 2500 yes (strong) 2.0
A549-T12 human lung A549 Taxol 9 no 3.4
A549-T24 human lung A549 Taxol 17 yes (weak) 9.5
A549-EP0.2 human lung A549 EPOBc 1.4 no 6.8
A549-EP0.3 human lung A549 EPOB 1.5 no 5.5
aP-gp, P-glycoprotein; bVBL, vinblastine; cEPOB, epothilone B.
dValues represent the average of two independent experiments.
Fig. 1. Expression of caveolin-1 and caveolin-2 in drug-sensitive and
-resistant SKOV3 and A549 cells. Lanes 1: SKOV3; lanes 2:
SKVLB1; lanes 3: A549; lanes 4: A549-T12 and lanes 5: A549-
T24. A and C: Lysates were prepared from vinblastine-sensitive and
-resistant SKOV3 cells and from Taxol-sensitive and -resistant A549
cells. After SDS-PAGE on a 12.5% gel and transfer to nitrocellu-
lose, immunoblotting was performed with mono-speci¢c antibody
probes that recognize only caveolin-1 (A) or caveolin-2 (C). B: Plas-
ma membranes from these cells were resolved by SDS-PAGE on a
5^13% gradient gel without boiling the samples, transferred to nitro-
cellulose, and probed with monoclonal antibody C219 against P-gly-
coprotein. The antibody dilution for the SKOV3 cell lines was
1:2500 and for the A549 series was 1:1000. ECL exposure time was
100 times shorter for the SKOV3 cell lines than for the A549 series.
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treated and Taxol-treated A549 cells with respect to caveolin-
1 (Fig. 3A). However, when 30^40% con£uent A549 cells were
treated with 10 nM Taxol and the expression of caveolin-1
was monitored over a longer period of time, it was found that
there was an increase in caveolin-1 expression beginning 48 h
after drug treatment. This increase continued for at least
4 days (Fig. 3B).
3.3. Expression of caveolins in epothilone B-resistant cells
Epothilone B is extremely cytotoxic to mammalian cells and
has a mechanism of action similar to that of Taxol [22]. A549-
EP0.2 and A549-EP0.3 were 1.4- and 1.5-fold resistant to
epothilone B, respectively. A competitive RT-PCR analysis
[5] indicated that there was no MDR1 gene expression in these
cells. In contrast, very low levels of MDR1 were detected in
A549-T24 and high levels were present in the very resistant
SKVLB1 cells (Fig. 4B). There was an approximate 5^7-fold
increase in caveolin-1 levels in A549-EP0.2 and A549-EP0.3
(Fig. 4A, left panel). Caveolin-2 levels remained similar in the
sensitive and Epothilone B-resistant A549 cells (Fig. 4A, right
panel).
4. Discussion
In this study, we have demonstrated (i) an increase in the
level of caveolin-1 in a 2500-fold vinblastine-resistant MDR
cell line, SKVLB1, that expresses high levels of P-glycoprotein
compared to its parental, drug-sensitive cell line SKOV3; (ii)
greater expression of caveolin-1 in 17-fold Taxol-resistant
A549 cells that do not express signi¢cant levels of P-glycopro-
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Fig. 2. Upregulation of caveolae organelles in Taxol-resistant A549-T24 cells. Samples were ¢xed with glutaraldehyde, post¢xed with osmium
tetroxide, and stained with uranyl acetate and lead citrate. Electron micrographs show views of the plasma membrane. A: Parental drug-sensi-
tive A549 cells. B: A549-T24 cells. C and D: Additional views of A549-T24 cells. Depending on the plane of the section, note that caveolae
can appear as free vesicles (B), attached omega-shaped £asks (C), or can be seen in bunches like clusters of grapes (D). Bar = 100 nm.
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tein, compared to drug-sensitive A549 cells ; (iii) a prominent
increase in caveolin-1 expression in a 9-fold Taxol-resistant
and in two approximately 1.5-fold epothilone B-resistant
A549 cells, all of which did not express any P-glycoprotein,
compared to A549 cells ; and (iv) increased expression of cav-
eolin-1 48 h after drug-sensitive A549 cells were treated with
10 nM Taxol.
Interestingly, an increase in caveolin-1 levels was observed
only in those cell lines that express caveolins endogenously.
For example, the expression of caveolin-1 and caveolin-2 was
not observed in several MDR cell lines that express high levels
of P-glycoprotein, such as J7.V1-1 [23] and J7.T3-1.6 [3] that
were derived from murine macrophage-like J774.2 cells, and
Caco-V100 that was derived in our laboratory from human
colon carcinoma Caco-2 cells (data not shown). Unlike epo-
thilone B-resistant A549 cells, epothilone B-resistant MCF-7
cells derived in our laboratory did not express any caveolins.
All of these parental drug-sensitive cells also did not express
caveolins. Although upregulation of caveolin-1 may represent
one component of resistance, it clearly is not a requirement
for the development of drug resistance.
It has been reported that glycosylceramides, the most
widely distributed glycosphingolipids in cells, accumulate in
various types of MDR cells [24]. Some agents that reverse
MDR, such as verapamil and cyclosporin A, block glyco-
sphingolipid metabolism by inhibiting ceramide glycosylation
in human cancer cells [25]. Since glycosphingolipids are im-
portant constituents of caveolae and caveolins are the princi-
pal components of caveolae, the role of caveolins in MDR
was investigated. However, our data demonstrate that the
induction of caveolin-1 expression does not require the expres-
sion of P-glycoprotein. For example, in low level Taxol-resist-
ant A549 cells, the induction of caveolin-1 expression occurs
independently of P-glycoprotein expression.
It has been proposed that microtubules are necessary for
the normal cycling of caveolin-1 between the plasma mem-
brane and the Golgi [26]. The introduction of Taxol, a mol-
ecule that stabilizes microtubules [27], may a¡ect the cycling
of caveolin-1. The presence of Taxol could result in an upre-
gulation of caveolin-1 as a way for the cell to compensate for
the e¡ect of the drug on the microtubule cytoskeleton.
We do not yet know the mechanism by which caveolin-1
levels are upregulated in the Taxol-resistant cells. Such upre-
gulation may occur at the level of transcriptional or transla-
tional control. Alternatively, upregulation of caveolin-1 could
also occur through gene ampli¢cation. However, our results
shown in Fig. 3 are more consistent with the former possibil-
ity, as caveolin-1 levels were upregulated acutely (within 48 h)
in response to Taxol treatment. Interestingly, several recent
reports have indicated that caveolin-1 levels also are elevated
in hormone-refractory prostate cancers [28^30].
Several lines of evidence indicate that Taxol can activate a
variety of signal transduction pathways. For example, (i) Tax-
ol activates c-jun N-terminal kinase (JNK) through both Ras
and apoptosis signal-regulating kinase (ASK1) pathways [8].
ASK1, a MAP kinase kinase kinase, causes the activation of
JNK and p38 and induces apoptotic cell death upon TNF-K
treatment [31]. (ii) Taxol induces activation of extracellular
signal-regulated kinases (ERK) [9^11]. Tyrosine phosphoryla-
tion of Shc and formation of a Shc/Grb2 complex also have
been demonstrated in Taxol-treated RAW 264.7 cells [11]. (iii)
Taxol causes tyrosine phosphorylation of p38 [32]. The inter-
action of signaling molecules with caveolin may in£uence Tax-
ol-induced signaling cascades that may undergo alterations
during the development of drug resistance.
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Fig. 3. Acute e¡ects of Taxol treatment on the expression of caveo-
lin-1 in drug-sensitive A549 cells. A549 cells were treated with 20^
1000 nM Taxol for 20 h, or treated with 10 nM Taxol for 1^4
days. Lysates were prepared and immunoblot analysis with anti-cav-
eolin-1 IgG (A and B) was performed as described in Section 2 and
as in Fig. 1. C: control cells ; T: 10 nM Taxol.
Fig. 4. Expression of caveolins in epothilone B-sensitive and -resist-
ant A549 cells. A: Lysates from drug-sensitive and epothilone B-re-
sistant A549 cells were prepared and immunoblotting was performed
with monoclonal antibodies against caveolin-1 (A, left panel) or cav-
eolin-2 (A, right panel). Lanes 1: A549 cells; lanes 2: A549-EP0.2
cells ; lanes 3: A549-EP0.3 cells. B: RT-PCR determination of
MDR1 gene expression was performed on SKVLB1 (lane 1, a highly
resistant MDR cell line), A549-T24 (lane 2, a relatively low Taxol-
resistant cell line), drug-sensitive A549 (lane 3), epothilone B-se-
lected A549-EP0.2 (lane 4) and A549-EP0.3 (lane 5) cells. Competi-
tive RT-PCR, involving coampli¢cation of MDR1 (167 bp) and
control L2-microglobulin (120 bp) gene sequences, was done for 35
cycles and the products were separated on an 11.5% polyacrylamide
gel followed by ethidium bromide staining as previously described
[5].
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In summary, our data indicate that Taxol induces the up-
regulation of caveolin-1 and caveolae organelles that could
play a role in Taxol-related drug resistance. Thus, caveolin-1
and caveolae organelles may represent novel therapeutic tar-
gets for molecules capable of modulating drug resistance in
those cells that have upregulated levels of caveolin-1.
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